

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 February 2022 (17.02.2022)



(10) International Publication Number

WO 2022/034504 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) A61K 31/4439 (2006.01)
A61K 31/4166 (2006.01) A61K 31/58 (2006.01)
A61K 38/00 (2006.01) A61P 35/00 (2006.01)
A61K 31/4164 (2006.01) A61P 35/04 (2006.01)

(21) International Application Number:

PCT/IB2021/057379

(22) International Filing Date:

10 August 2021 (10.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/065,160 13 August 2020 (13.08.2020) US

(71) Applicants: **PFIZER INC.**, [US/US]; 235 East 42nd Street, New York, New York 10017 (US). **ASTELLAS PHARMA INC.**, [JP/JP]; 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo, 103-8411 (JP).

(72) Inventors: **ANDERS, Lars**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **KIM, Kimberly Hyunjung**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **LI, Danan**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **MCMILLAN, Elizabeth Anne**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **ROLLINS, Robert Andrew**; c/o Pfizer Inc., 235 East 42nd Street, New York, New York 10017

(US). **VEENEMAN, Brendan Ayers**; 25 Executive Dr., Unit 301, Stoneham, Massachusetts 02180 (US).


(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd Street, MS 235/9/86, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMBINATION THERAPY

FIG. 1B



(57) Abstract: This invention relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) or a pharmaceutically acceptable salt thereof, and an antiandrogen, optionally in further combination with an additional anti-cancer agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*